What is CUSIP 09075P105?

CUSIP 09075P105 is the security identifier used in SEC filing datasets for BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001.

Security Snapshot

BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) Institutional Ownership

Q: Who owns BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CUSIP: 09075P105

13F Institutional Holders and Ownership History from Q1 2018 to Q4 2025

Latest Period

n/a

Institutions Reporting

Shares (Excl. Options)

Price

$0.17

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Type / Class: Equity / Common Stock, par value $0.001
Symbol: BTAI on Nasdaq
Shares outstanding: 27,093,277
Price per share: $0.17

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Key facts

BTAI - BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 is tracked under CUSIP 09075P105.
Latest finished 13F holder period is not available.
3 significant owners is listed from Schedule 13D/13G reporting.

Change

Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
Reported value moved from $54 to $0.

Research use

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Evidence

Source: SEC Schedule 13D/G

Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.

Open SEC Evidence

Security key

09075P105

Latest holder period

n/a

13F holders

13D/G owners

CIK / CUSIP context first

BTAI full holder history BioXcel Therapeutics, Inc. SEC filings BioXcel Therapeutics, Inc. company facts BioXcel Therapeutics, Inc. insider transactions

Broader feeds

Latest 13F filings Latest 13D/G filings All securities

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 09075P105:

Q4 2025 (0 holders) Q3 2025 (1 holder) Q2 2025 (1 holder) Q1 2025 (0 holders) Q4 2024 (47 holders) Q3 2024 (46 holders) Q2 2024 (71 holders) Q1 2024 (71 holders) Q4 2023 (72 holders) Q3 2023 (82 holders)

Significant Owners of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
ARMISTICE CAPITAL, LLC	7%		$324,713		1,910,076		Armistice Capital, LLC	31 Mar 2026
Oaktree Capital Group Holdings GP, LLC	2.7%	-49%	$28,939	-$434,154	170,230	-94%	Oaktree Capital Holdings, LLC	31 Mar 2025
Qatar Investment Authority	0.6%	-92%	$26,531	-$436,562	156,066	-94%	Qatar Investment Authority	31 Dec 2025

Institutional Holders of BioXcel Therapeutics, Inc. - Common Stock, par value $0.001 (BTAI) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	0	$0	-$54			$0.17	0
2025 Q3	88	$54	+$54			$0.61	1
2025 Q2	14,875	$5,503	+$5,503			$0.37	1
2025 Q1	0	$0	-$3,224,068	$0	$0	$0.17	0
2024 Q4	8,627,682	$3,224,936	+$2,041,377	$22,210	$12,900	$0.37	47
2024 Q3	3,099,756	$1,890,127	-$7,944,274	$24,522	$13,542	$0.61	46
2024 Q2	9,738,748	$12,466,903	-$1,711,528	$262,954	$129,152	$1.28	71
2024 Q1	9,238,957	$26,053,732	-$415,412	$624,603	$239,700	$2.82	71
2023 Q4	9,351,765	$27,595,077	-$1,941,847	$966,519	$238,950	$2.95	72
2023 Q3	10,142,059	$25,655,976	-$27,908,890	$550,781	$928,763	$2.53	82
2023 Q2	17,642,933	$117,491,802	-$7,226,324	$3,935,434	$3,112,218	$6.66	83
2023 Q1	17,417,079	$324,965,795	+$71,330,482	$3,286,026	$4,898,250	$18.66	96
2022 Q4	13,442,183	$288,837,441	+$37,768,271	$1,250,136	$2,788,104	$21.48	81
2022 Q3	11,865,502	$140,259,937	-$11,714,266	$820,000	$1,831,000	$11.82	82
2022 Q2	12,674,614	$167,321,205	-$8,492,233	$1,592,000	$1,846,000	$13.20	90
2022 Q1	13,111,117	$273,902,967	-$16,331,751	$4,063,000	$3,230,000	$20.91	93
2021 Q4	13,927,053	$283,060,517	+$19,228,913	$2,596,000	$3,108,000	$20.33	90
2021 Q3	12,791,796	$388,253,110	-$6,408,094	$6,152,000	$6,161,000	$30.35	103
2021 Q2	13,030,148	$378,637,038	+$41,282,735	$7,322,000	$4,501,000	$29.06	108
2021 Q1	11,015,188	$475,171,234	-$56,530,789	$9,456,000	$10,301,000	$43.16	114
2020 Q4	12,260,234	$566,451,752	+$16,958,479	$11,102,000	$26,762,000	$46.20	114
2020 Q3	11,873,463	$514,719,363	+$152,548,583	$6,024,000	$21,530,000	$43.36	107
2020 Q2	8,121,087	$430,587,215	+$116,997,084	$11,788,000	$24,304,000	$53.01	103
2020 Q1	5,997,060	$133,825,071	+$39,824,964	$1,933,000	$3,956,000	$22.35	68
2019 Q4	4,342,692	$63,268,018	+$1,450,806			$14.61	42
2019 Q3	4,179,707	$29,412,098	+$8,120,529			$7.04	41
2019 Q2	2,932,356	$32,048,175	+$4,610,881			$10.96	34
2019 Q1	2,512,687	$24,935,000	+$931,694			$9.89	19
2018 Q4	2,420,717	$9,354,000	-$3,409,943			$3.85	11
2018 Q3	3,251,790	$24,996,000	-$3,807,303			$7.66	17
2018 Q2	3,723,565	$34,207,000	-$9,901,055			$9.20	19
2018 Q1	4,695,186	$47,920,000	+$47,920,000			$10.24	22